3Chopt Investment Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

3Chopt Investment Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.65M	Sell	3,695 -491	-12%	-$229K	0.38%	59
2025 Q4	$1.9M	Sell	4,186 -247	-6%	-$106K	0.43%	58
2025 Q3	$1.74M	Sell	4,433 -479	-10%	-$200K	0.4%	61
2025 Q2	$2.19M	Sell	4,912 -367	-7%	-$169K	0.53%	48
2025 Q1	$2.56M	Sell	5,279 -442	-8%	-$206K	0.67%	38
2024 Q4	$2.3M	Sell	5,721 -1,316	-19%	-$610K	0.79%	41
2024 Q3	$3.27M	Sell	7,037 -905	-11%	-$435K	1.17%	25
2024 Q2	$3.72M	Buy	7,942 +122	+2%	+$53K	1.14%	14
2024 Q1	$3.27M	Buy	7,820 +1,033	+15%	+$437K	1.34%	18
2023 Q4	$2.76M	Buy	6,787 +856	+14%	+$316K	1.02%	20
2023 Q3	$2.06M	Buy	5,931 +112	+2%	+$39.2K	1.22%	31
2023 Q2	$2.05M	Sell	5,819 -276	-5%	-$93K	1.02%	32
2023 Q1	$1.92M	Buy	6,095 +493	+9%	+$148K	1.02%	31
2022 Q4	$1.62M	Buy	+5,602	New	+$1.71M	0.88%	38

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

3Chopt Investment Partners's VRTX Position: Q1 2026 in Review

3Chopt Investment Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 12% in Q1 2026, selling an estimated $229K and leaving 3,695 shares worth $1.65M. The position accounts for 0.38% of the portfolio, ranked #59.

3Chopt Investment Partners first reported a position in VRTX in Q4 2022 and has held it in 14 quarters since. The position peaked at $3.72M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

3Chopt Investment Partners held 3,695 shares of Vertex Pharmaceuticals worth $1.65M as of Q1 2026.
3Chopt Investment Partners sold 491 Vertex Pharmaceuticals shares in Q1 2026, an estimated $229K.
Vertex Pharmaceuticals made up 0.38% of 3Chopt Investment Partners's portfolio in Q1 2026, its #59 holding.
3Chopt Investment Partners first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
3Chopt Investment Partners's Vertex Pharmaceuticals position peaked at $3.72M in Q2 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on 3Chopt Investment Partners's 13F filing for Q1 2026, filed 23 Apr 2026.